Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P749: A comparative analysis of low bioavailability steroids in inducing clinical response and remission in ulcerative colitis: Budesonide MMX as the safest optionECCO '18 Vienna
Year: 2018
Authors:

B. Scrivo, E. Giuffrida, V. Calvaruso, M. Cappello*

Gastroenterology Section, DiBiMis, University of Palermo, Palermo, Italy

P750: Predictors of quick remission after cyclosporine A therapy in Paediatric ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

M. Osiecki*, M. Dadalski, J. Kierkus

The Children's Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

P751: Time course of the incidence and magnitude of anti-drug antibodies to adalimumab and ABP 501 among patients on concomitant immunomodulatory therapyECCO '18 Vienna
Year: 2018
Authors:

D. Mytych*, J. Miller, M. Starcevic Manning, I. Wala, H. Wang, N. Zhang, E. Krishnan, A. Kaliyaperumal

Amgen Inc., Biosimilars, Thousand Oaks, USA

P752: Oral once daily budesonide granules rapidly induce clinical remission in Lymphocytic Colitis: A double-blind, double-dummy, multi-centre, randomised trialECCO '18 Vienna
Year: 2018
Authors:

S. Miehlke1*, D. Aust2, E. Mihaly3, P. Armerding4, G. Böhm5, O. Bonderup6, F. Fernández-Bañares7, J. Kupcinskas8, L.K. Munck9, K.-U. Rehbehn10, T. Nacak11, R. Greinwald11, A. Münch12

1Center for Inflammatory and Digestive Diseases Eppendorf, Hamburg, Germany, 2University Hospital, Institute of Pathology, Dresden, Germany, 3Semmelweis University, Budapest, Hungary, 4Private Practice for Gastroenterology, Berlin, Germany, 5Private Practice, Ludwigshafen, Germany, 6Silkeborg Hospital, Diagnostic Center, Silkeborg, Denmark, 7Hospital Universitari Mutua Terrassa, Department of Gastroenterology, Terrassa, Spain, 8University of Health Sciences, Kaunas, Lithuania, 9Køge Hospital, Department of Medical Gastroenterology, Køge, Denmark, 10Private Practice, Solingen, Germany, 11Dr. Falk Pharma GmbH, Clinical Research, Freiburg, Germany, 12Linköping University, Division of Gastroenterology and Hepatology, Linköping, Germany

P753: Vedolizumab trough levels during induction in IBD patients: A longitudinal observational retrospective studyECCO '18 Vienna
Year: 2018
Authors:

C. Liefferinckx1,2*, A. Cremer1,2, C. Minsart2, A. Gils3, L. Amininejad1, V. Tafciu2, E. Quertinmont2, J. Devière1,2, A. Van Gossum1, D. Franchimont1,2

1Hopital Erasme, ULB, Department of gastroenterology, Brussels, Belgium, 2Université libre de bruxelles, Laboratory of Experimental Gastroenterology, Brussels, Belgium, 3KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

P754: Short-term and long-term outcome for dilation therapy of stricturing Crohn’s disease of the small intestine using balloon-assisted endoscopy - a combined analysis of 1194 endoscopic balloon dilation proceduresECCO '18 Vienna
Year: 2018
Authors:

D. Bettenworth1,2*, A. Bokemeyer1, R. Lopez3, F. Rieder4,5

1University Hospital Münster, Department of Medicine B, Gastroenterology and Hepatology, Münster, Germany, 2University Hospital Münster, Department of Medicine B, Münster, Germany, 3Cleveland Clinic Foundation, Cleveland, Ohio, USA, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, USA, 4Cleveland Clinic Foundation, Cleveland, Ohio, USA, Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease Institute, Cleveland, USA, 5Cleveland Clinic Foundation, Cleveland, Ohio, USA, Department of Pathobiology, Lerner Research Institute, Cleveland, USA

P755: Safety, efficacy, and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-TNFECCO '18 Vienna
Year: 2018
Authors:

S. Ben-Horin1*, B. Ungar1, U. Kopylov1, A. Lahat1, M. Yavzori1, E. Fudim1, O. Picard1, Y. Peled2, R. Eliakim1, E. Del Tedesco3, S. Paul4, X. Roblin4

1Sheba Medical Center and Sackler School of Medicine, Gastroenterology, Tel Hashomer, Israel, 2Sheba Medical Center and Sackler School of Medicine, Institute of Clinical Pharmacology, Tel Hashomer, Israel, 3CHU de Saint-Etienne, Service de Gastrologie-Entérologie-Hépatologie, Saint-Etienne, France, 4University Hospital of Saint Etienne, Department of Gastroenterology, Saint Etienne, France

P756: Comorbidities in adolescents with inflammatory bowel disease: Findings from a population-based cohortECCO '18 Vienna
Year: 2018
Authors:

I. Ghersin1*, L.H. Katz2, S. Daher3, R. Shamir4, A. Assa4

1Rambam Health Care Campus, Haifa, Israel, 2Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 3IDF Medical Corps, Tel Hashomer, Israel, 4Schneider Children's Medical Center, Gastroenterology, Petach Tikva, Israel

P757: Long-term effectiveness and safety of adalimumab based on Crohn’s disease duration: Results from the PYRAMID registryECCO '18 Vienna
Year: 2018
Authors:

E.V. Loftus Jr.1*, W. Reinisch2, R. Panaccione3, S. Berg4, M. Bereswill5, J. Kalabic5, M. Skup6, J. Petersson6, A.M. Robinson6, G. D'Haens7

1Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, USA, 2Medical University of Vienna, Vienna, Austria, 3University of Calgary, Calgary, Canada, 4AbbVie AB, Solna, Sweden, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 6AbbVie Inc., North Chicago, USA, 7Academic Medical Center, Amsterdam, The Netherlands

P758: Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn’s disease (SVEAH CD)ECCO '18 Vienna
Year: 2018
Authors:

C. Eriksson1, S. Rundquist1*, V. Lykiardopoulos2, P. Karlén3, O. Grip4, C. Söderman5, S. Almer6, E. Hertervig7, J. Gunnarsson8, C. Malmgren9, J. Delin10, H. Strid11, M. Sjöberg12, D. Öberg13, D. Bergemalm1, R. Udumyan14, H. Hjortswang2, The SWIBREG SVEAH Study Group, J. Halfvarson1

1Faculty of Medicine and Health, Örebro University, Department of Gastroenterology, Örebro, Sweden, 2Linköping University, Department of Gastroenterology, Linköping, Sweden, 3Danderyd Hospital, Department of Internal Medicine, Stockholm, Sweden, 4Skåne University Hospital, Department of Gastroenterology, Malmö, Sweden, 5St Göran Hospital, Department of Internal Medicine, Stockholm, Sweden, 6Karolinska Institute, Department of Medicine, Stockholm, Sweden, 7Skåne University Hospital, Department of Gastroenterology, Lund, Sweden, 8Kungsbacka Hospital, Department of Internal Medicine, Kungsbacka, Sweden, 9Takeda Pharma AB, Solna, Sweden, 10Ersta Hospital, Department of Gastroenterology, Stockholm, Sweden, 11Södra Älvsborgs Hospital, Department of Internal Medicine, Borås, Sweden, 12Skaraborgs Hospital, Department of Internal Medicine, Lidköping, Sweden, 13Sunderby Hospital, Department of Internal Medicine, Sunderbyn, Sweden, 14Örebro University, Clinical Epidemiology and Biostatistics, Örebro, Sweden

P759: Ustekinumab as rescue treatment in therapy-refractory or -intolerant ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

T. Ochsenkühn1,2*, S. Janelidze2, C. Tillack2,3, F. Beigel3

1Isarklinikum, Gastroenterology, Munich, Germany, 2Synesis, IBD research center, Munich, Germany, 3University of Munich, Gastroenterology, Munich, Germany

P760: Monitoring of laboratory parameters during thiopurine maintenance therapy in patients with inflammatory bowel disease: An unnecessary burden?ECCO '18 Vienna
Year: 2018
Authors:

J.E. Kreijne1*, A.C. de Vries1, G. Bouma2, G. Dijkstra3, M.D. Voskuil3, R.L. West4, A.A. van Bodegraven5, D.J. de Jong6, N.K. de Boer2, C.J. van der Woude1

1Erasmus MC, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 2VU University Medical Centre, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 3University Medical Center Groningen and University of Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, 4Franciscus Hospital and Vlietland Hospital, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 5Zuyderland Medical Center, Clinical Gastroenterology and Hepatology, Heerlen-Sittard-Geleen, The Netherlands, 6Radboud University Nijmegen Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands

P761: IFX dose-escalation strategy based on a population PK model in IBD patients with secondary loss of responseECCO '18 Vienna
Year: 2018
Authors:

J. Guardiola1*, L. Rodriguez Alonso1, K. Serra1, E. Santacana2, H. Colom3, F. Rodríguez-Moranta1, P. Gilabert1, C. Arajol1, E. Sanchez Pastor1, J. Bas4, A. Padullés2, N. Padullés2

1Hospital Universitario de Bellvitge, Gastroenterology, L´Hospitalet de Llobregat, Spain, 2Hospital Universitario de Bellvitge, Pharmacy, L´Hospitalet de LLobregat, Spain, 3Universitat de Barcelona, Pharmacy and pharmaceutical technology, Barcelona, Spain, 4Hospital Universitario de Bellvitge, Immunology, L´Hospitalet de LLobregat, Spain

P762: GO-CARE: A prospective multi-centre observational study of golimumab effectiveness and quality of life in a real-life UC patient population in ItalyECCO '18 Vienna
Year: 2018
Authors:

A. Armuzzi1*, S. Marchi2, A. Gasbarrini3, S. Saibeni4, A. Geccherle5, M. Principi6, V. Germano7, F. Bossa8, A.C. Privitera9

1IBD Unit, Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, 2Division of Gastroenterology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, 3Internal Medicine, Gastroenterology and Liver Unit, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy, 4Gastroenterology Unit, RhoHospital, Rho, Italy, 5Intestinal Bowel Disease Unit,Ospedale Sacro Cuore Don Calabria, Negrar Verona, Italy, 6Gastroenterology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, 7MSD, Roma, Italy, 8Division of Gastroenterology, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo Foggia, Italy, 9IBD and Pelvic Floor Unit, Azienda ospedaliera per l'emergenza, Ospedale Cannizzaro, Catania, Italy

P763: Quality of life in Paediatric inflammatory bowel disease Patient: How well do we understand patients?ECCO '18 Vienna
Year: 2018
Authors:

S. Kim, S. Park, Y. Kang, H. Koh

Severance Children's Hospital, Department of Pediatrics, Seoul, South Korea

P764: Drug level thresholds in patients with Crohn’s disease on dose-intensified anti-TNF therapy predict intestinal wall healing for infliximab but not adalimumabECCO '18 Vienna
Year: 2018
Authors:

R. Little*, H. Su, A. Friedman, S. Williams, P. Gibson, M. Ward, K. Taylor, M. Sparrow

Alfred Health and Monash University, Gastroenterology, Melbourne, Australia

P765: Role of C-reactive protein kinetics after surgery for Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

M. Carvello*, F. Di Candido, G. Fiorino, S. Danese, A. Spinelli

Humanitas Research Hospital, Rozzano, Milan, Italy

P766: Quantum Blue® fCAL extended POC user performance evaluationECCO '18 Vienna
Year: 2018
Authors:

B. Fellay1, M. Drzewicka2, E. Burri3, M.-E. Ueberschlag4, A. Ritz4, J. Wieland4, M. Schneider4*

1Hôpital Cantonal Fribourg, Fribourg, Switzerland, 2Szpital Pediatryczny w Bielsku-Białej, Bielsko-Biała, Poland, 3Kantonsspital Baselland, Liestal, Switzerland, 4BÜHLMANN Laboratories AG, Schoenenbuch, Switzerland

P767: Quantum Blue® infliximab POC user performance evaluationECCO '18 Vienna
Year: 2018
Authors:

B. Fellay1, M. Kopertowska-Majchrzak2, E. Burri3, M.-E. Ueberschlag4, A. Ritz4, T. Schuster4*

1Hôpital Cantonal Fribourg, Fribourg, Switzerland, 2Wielospecjalistyczny Szpital Wojewódzki, Gorzów Wlkp, Poland, 3Kantonsspital Baselland, Liestal, Switzerland, 4BÜHLMANN Laboratories AG, Schoenenbuch, Switzerland

P768: Extended enoxaparin venous thromboembolism prophylaxis after surgery for inflammatory bowel disease: A cost-based decision-analysisECCO '18 Vienna
Year: 2018
Authors:

S. Holubar1*, P. Dulai2, B. Piazik3, S. Finlayson4, B. Udeh5

1Cleveland Clinic, Department of Colon and Rectal Surgery, Cleveland, USA, 2University of California San Diego, Medicine, San Diego, USA, 3Elliot Health Systems, Manchester, USA, 4University of Utah, Surgery, Salt Lake City, USA, 5Cleveland Clinic, Clinical Transformation, Cleveland, USA